Updates are available Correction dated 2022-12-20
Click to view Correction: https://doi.org/10.1007/s00262-022-03351-w
-
Authors
Weber, Jeffrey S. http://orcid.org/0000-0002-4962-2957
Poretta, Tayla
Stwalley, Brian D.
Sakkal, Leon A.
Du, Ella X.
Wang, Travis
Chen, Yan
Wang, Yan
Betts, Keith A. http://orcid.org/0000-0002-3088-7453
Shoushtari, Alexander N. http://orcid.org/0000-0002-8065-4412
-
Funding
Funding for this research was provided by:
Bristol Myers Squibb
a National Cancer Institute (NCI) Cancer Center Core Grant to ANS (P30CA008748)
- License Information
-
More Information
Article History
Received: 10 August 2022
Accepted: 23 September 2022
First Online: 5 October 2022
Change Date: 20 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00262-022-03351-w
Declarations
:
: JSW reports stock ownership in Biond, CytoMx, Evaxion, NexImmune, and Protean; receiving consulting or advisory fees from AstraZeneca, Biond, Bristol Myers Squibb (BMS), Celldex, CytomX, Evaxion, GlaxoSmithKline (GSK), Genentech, Idera, Incyte, Merck, NexImmune, Novartis, OncoSec, Pfizer, Ultimovacs, Regeneron, and Sellas; receiving research funding from BMS, GSK, Merck, Moderna, Novartis, and Regeneron; holding patents issued for a PD-1 biomarker named by Biodesix and a CTLA-4 biomarker named by Moffitt Cancer Center. TP reports being an employee of BMS with stock ownership in BMS. BDS reports being an employee of BMS with stock ownership in AbbVie, BMS, and Gilead Sciences Inc. LAS reports being an employee of BMS with stock ownership in BMS. EXD reports being an employee of the Analysis Group, Inc., which received consultancy fees from BMS for conducting the research analysis for the work under consideration. TW reports being an employee of the Analysis Group, Inc., which received consultancy fees from BMS for conducting the research analysis for the work under consideration. YC reports being an employee of the Analysis Group, Inc., which received consultancy fees from BMS for conducting the research analysis for the work under consideration. YW reports being an employee of the Analysis Group, Inc., which received consultancy fees from BMS for conducting the research analysis for the work under consideration. KAB reports being an employee of the Analysis Group, Inc., which received consultancy fees from BMS for conducting the research analysis for the work under consideration. ANS reports receiving advisory or personal fees from BMS, Immunocore, and Novartis; receiving research funding to his institution from BMS, Checkmate Pharmaceuticals, Foghorn Therapeutics, Immunocore, Novartis, Pfizer, Polaris, Targovax, and Xcovery.
: All study participants provided informed consent and both trials were approved by their respective Institutional Review Boards and were conducted under the Declaration of Helsinki.
